Emerging Trends to Reshape the Osteoarthritis Market: Partnership Approaches And Advanced Treatments Transform The Osteoarthritis Market as a Key Influencer

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

Osteoarthritis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market scale for osteoarthritis has experienced significant growth in the previous years. A rise from $6.87 billion in 2024 to $7.53 billion in 2025, with a compound annual growth rate (CAGR) of 9.6%, is expected. The expansion during the historic timeframe is due to factors such as an aging populace, the obesity crisis, advancements in imaging technology, and progress in pain relief.

Osteoarthritis Market Size Forecast: What's the Projected Valuation by 2029?
The market for osteoarthritis is projected to experience significant expansion in the upcoming years, reaching a valuation of $10.64 billion by 2029 at a compound annual growth rate (CAGR) of 9.0%. The anticipated growth through the forecast period can be credited to factors such as non-pharmacological methods, disease-modifying osteoarthritis drugs (dmoads), customized medicine, telehealth, and distant monitoring. The forecast period is also expected to witness major trends like regenerative therapies, wearable technologies, the application of artificial intelligence in diagnosis, and digital healthcare tools.

View the full report here:
https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

What Are the Drivers Transforming the Osteoarthritis Market?
As obesity-related disorders rise, it is anticipated that the osteoarthritis market will experience increased growth. These disorders, which are linked to an excess of body fat, are brought on by consuming more calories than the body exhausts through physical activity, excessive intake of processed and fast foods, and overconsumption of alcohol. The extra weight and strain put on joints due to obesity can lead to osteoarthritis, as it often results in joint inflammation and hormonal alterations. The World Obesity Atlas 2022 from the UK-based World Obesity Federation predicts that by 2030, 1 billion individuals globally, or one in seven men and one in five women, will live with obesity. This number is projected to increase to 4 billion, or 51% of the global population, who will be either overweight or obese by 2035. Thus, the rise in obesity-related disorders signifies a growth driver for the osteoarthritis market. An additional factor triggering the expansion of the osteoarthritis market is the ubiquitous use of painkillers. Painkilling medications or substances, which work by reducing pain perception, can alleviate the discomfort associated with various conditions or injuries. Their extensive usage in tackling osteoarthritis, fueled by the demand for effective pain relief, is likely to significantly affect the osteoarthritis market. It can lead to increased demand, affect treatment protocols, encourage research and development initiatives, and spread awareness about the condition. According to a June 2022 survey by the US-based Consumer Healthcare Products Association, about 80% of respondents stated that their usage of over-the-counter pain relievers has either remained consistent (49%) or heightened (30%) over the past two years. Therefore, the extensive use of painkillers is fuelling the expansion of the osteoarthritis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13022&type=smp

What Long-Term Trends Will Define the Future of the Osteoarthritis Market?
To expand their technological capabilities and broaden their market footprint, many leading businesses involved in the osteoarthritis market are strategically partnering with other organizations. This strategic partnership involves a cooperative agreement between two or more entities to pool their resources, knowledge, and efforts to realize common aims and objectives. For example, LG Chem, a prominent pharmaceutical firm from South Korea, made its entrance into the Chinese market in July 2024. This was made possible through its collaboration with Yifan Pharmaceutical Co., Ltd., a Chinese company renowned for its pharmaceutical research and production. Their joint endeavor resulted in the roll-out of Synovian injection for osteoarthritis, which mimics the therapeutic effects of traditional multi-injection formulations but only requires a single administration. Key aspects of Synovian that set it apart include its use of high molecular (10 million Dalton) hyaluronic acid, which improves viscoelasticity and joint function, along with proven clinical phase 3 trial data indicating its significant effect in reducing knee pain. This breakthrough cements Synovian's status as an attractive solution for patients seeking easy mitigation of their osteoarthritis symptoms.

Which Segments in the Osteoarthritis Market Offer the Most Profit Potential?
The osteoarthritis market covered in this report is segmented -

1) By Treatment: Medication, Surgery, Therapy
2) By Diagnosis: Imaging, Joint Fluid Analysis
3) By Route Of Administration: Parenteral Route, Topical Route, Oral Route
4) By Disease Type: Knee Osteoarthritis, Spine Osteoarthritis, Foot And Ankle Osteoarthritis, Shoulder Osteoarthritis, Hand Osteoarthritis
5) By End-User: Hospitals, Medical Institutes

Subsegments:
1) By Medication: Pain Relievers, Corticosteroids, Hyaluronic Acid Injections, Disease-Modifying Osteoarthritis Drugs (DMOADs)
2) By Surgery: Joint Replacement Surgery, Arthroscopy, Osteotomy, Joint Fusion
3) By Therapy: Physical Therapy, Occupational Therapy, Weight Management Programs, Assistive Devices

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13022&type=smp

Which Firms Dominate the Osteoarthritis Market by Market Share and Revenue in 2025?
Major companies operating in the osteoarthritis market are Pfizer Inc., Johnson & Johnson, Merck Sharp & Dohme Corp., Abbvie Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories Incorporation, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Reckitt Benckiser Group PLC, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Astellas Pharma Inc., Zimmer Biomet Holdings Inc., Eisai Co. Ltd., Horizon Therapeutics PLC, Apotex Inc., Mallinckrodt Pharmaceuticals, Pacira BioSciences Inc., Bioventus Inc., Endo Pharmaceuticals Inc., Assertio Therapeutics Inc., Anika Therapeutics Inc., Abiogen Pharma Spa, Kolon TissueGene Inc., Ampio Pharmaceuticals Inc.

Which Regions Offer the Highest Growth Potential in the Osteoarthritis Market?
North America was the largest region in the osteoarthritis market in 2024. The regions covered in osteoarthritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13022

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.